Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage

Table 4 Comparison of response in both hepatitis C groups according to histopathological changes n (%)

Variable	n	Responders	Non responders	Among responders
				Sustained response	Relapse
Severe Fibrosis
A1	13	8 (61.5)	5 (38.5)	5 (62.5)	3 (37.5)
B2	11	1 (9.1)	10 (90.9)	0 (0.0)	1 (100.0)
Mild fibrosis
A1	25	21 (84.0)	4 (15.0)	20 (95.2)	1 (4.8)
B2	24	13 (54.2)	11 (45.8)	9 (69.2)	4 (30.8)
Severe inflammation
A1	31	22 (71.0)	9 (29.0)	18 (81.8)	4 (18.2)
B2	27	7 (25.9)	20 (74.1)	4 (57.1)	3 (42.9)
Mild inflammation
A1	7	7 (100.0)	0 (0.0)	7 (100.0)	0 (0.0)

¹Group A = PEG-IFN+RBV;

²Group B = IFN + RBV.